MannKind Corporation to acquire scPharmaceuticals, enhancing revenue growth in cardiometabolic and lung diseases.
The acquisition includes an upfront cash payment of $5.35 per share with additional contingent value rights.
FUROSCIX, a treatment for edema in heart failure and kidney disease, is a key asset in the acquisition.
Revenue Growth Acceleration
Acquisition expected to diversify and accelerate double-digit revenue growth.
Strategic Expansion
MannKind strategically expands into cardiorenal medicine with the scPharmaceuticals acquisition.
Commercial Momentum
scPharmaceuticals shows strong commercial momentum with significant year-over-year growth.
Product Innovation
FUROSCIX ReadyFlow Autoinjector potentially unlocking additional market opportunities.
- The acquisition is expected to diversify MannKind's revenue base with three commercial assets and a projected annualized run rate of over $370 million.
- Integration of scPharmaceuticals' capabilities into MannKind aims to unlock growth opportunities in the cardiometabolic market.
The acquisition of scPharmaceuticals marks a significant step for MannKind Corporation in its commitment to delivering innovative therapies for cardiometabolic and orphan lung diseases.